"Great innovations and new medicines are emerging in the animal health space, especially in terms of biologics and monoclonal antibodies, and we saw great opportunities in this developing area."
"We now offer an open platform for life sciences companies to have conversations around priorities in their field and discuss challenges in the supply chain."
"We progressed on the development of our New Innovative Products (NIP), which are complex generics developed using in-house proprietary technology platforms."
"We are beginning to see California move forward as not two or three individual clusters, but rather as a powerhouse of integrated clusters, and this will continue to be our focus in the future."
"In 2023, Massachusetts made up just shy of 15% of the national drug development pipeline and approximately 7% of the global drug development pipeline."
Featuring insights from nearly 50 mining executives, the second pre-release edition of GBR's Peru Mining 2025 sheds light on the industry's current state while highlighting the country's window of opportunity with the energy transition and copper's critical role.